1McKenna WJ,Camm AJ. Sudden death in hypertrophic cardiomyopathy:assessment of patient at high risk[J]. Circulation,1989,80∶1489-1492.
2Nishimura RA,Trusty JM,Hayes DL,et al. Dual-chamber pacing for hypertrophic cardiomyopathy:a randomized,double-blind,crossover trial[J]. J Am Coll Cardiol,1997,29∶435-441.
3Nagueh SF,Ommen SR,Lakkis NM,et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy[J]. J Am Coll Cardiol,2001,38∶1701-1706.
4Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J]. Lancet,1995,346∶211-214.
5Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy[J]. Curr Cardiol Rep,2001,3∶160-166.
6Faber L,Seggewiss H,Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy:results with respect to intraprocedural myocardial contrast echocardiography[J]. Circulation,1998,98∶2415-2421.
7Faber L,Seggewiss H,Ziemssen P,et al. Intraprocedural Myocardial Contrast Echocardiography as a Routine Procedure in Percutaneous Transluminal Septal Myocardial Ablation:Detection of threatening myocardial necrosis distant from the septal target area[J]. Catheter Cardiovasc Interv,1999,47∶462-466.
3Lazzeroni E, Dornenicucci S, Finardi A, et al Severity of an-hythmias and extent of hypertrophy in hypertrophic cardiomyopathy[J]. Am Heart J, 1989, 118: 734.
4郭行远.心肌病学[M].杭州:浙江科学出版社,2000:40-57.
5Faber L, Seggewiss H, Gleichmann U. Percutaneous Transluminal septal myocardial ablation in hypertrophic obstructive eardiomyopathy. Results with respect to intraprocedural myocardial contrast echocardiography [J]. Circulation, 1998, 98:2415 -2421.
8Airolst FD,Mario C.Proaressive decrease of outflow gradient andseptum thickness after percutaneous alcoholization of the in-terventricular septum in hypertrophic obstructive oardiomyopa-thy[J].Ital Heart J,2000,1(3):200-206.
